Respiratory syncytial virus sequencing considerations for an expanded Global Influenza Surveillance and Response System
World Health Organization
ມິ.ຖ. 2025 · World Health Organization
ປຶ້ມອີບຸກ
35
ໜ້າ
family_home
ມີສິດ
info
reportບໍ່ໄດ້ຢັ້ງຢືນການຈັດອັນດັບ ແລະ ຄຳຕິຊົມ ສຶກສາເພີ່ມເຕີມ
ກ່ຽວກັບປຶ້ມ e-book ນີ້
In recent years, rapid progress has been made in the development of new pharmaceutical interventions against respiratory syncytial virus (RSV), including monoclonal antibodies (mAbs), vaccines and antivirals. Both passive immunization and active immunization against RSV have now been recommended for infants and older adults in several countries. The ongoing surveillance of RSV viruses is thus vital for identifying the appropriateness of diagnostics and interventions. Establishing a baseline understanding of RSV sequence diversity prior to the widespread rollout of immunization will help to inform the development of new diagnostic and therapeutic products, facilitate assessment of the effectiveness of immunization programmes, better understand viral diversity and evolution, and assess the potential impact of RSV variants on the effectiveness of interventions. This document outlines a number of practical considerations regarding the scale and quality of sequencing. It also outlines the range of next generation sequencing (NGS) technologies suitable for RSV whole genome sequencing (WGS).
ໃຫ້ຄະແນນ e-book ນີ້
ບອກພວກເຮົາວ່າທ່ານຄິດແນວໃດ.
ອ່ານຂໍ້ມູນຂ່າວສານ
ສະມາດໂຟນ ແລະ ແທັບເລັດ
ຕິດຕັ້ງ ແອັບ Google Play Books ສຳລັບ Android ແລະ iPad/iPhone. ມັນຊິ້ງຂໍ້ມູນໂດຍອັດຕະໂນມັດກັບບັນຊີຂອງທ່ານ ແລະ ອະນຸຍາດໃຫ້ທ່ານອ່ານທາງອອນລາຍ ຫຼື ແບບອອບລາຍໄດ້ ບໍ່ວ່າທ່ານຈະຢູ່ໃສ.
ແລັບທັອບ ແລະ ຄອມພິວເຕີ
ທ່ານສາມາດຟັງປຶ້ມສຽງທີ່ຊື້ໃນ Google Play ໂດຍໃຊ້ໂປຣແກຣມທ່ອງເວັບຂອງຄອມພິວເຕີຂອງທ່ານໄດ້.
eReaders ແລະອຸປະກອນອື່ນໆ
ເພື່ອອ່ານໃນອຸປະກອນ e-ink ເຊັ່ນ: Kobo eReader, ທ່ານຈຳເປັນຕ້ອງດາວໂຫຼດໄຟລ໌ ແລະ ໂອນຍ້າຍມັນໄປໃສ່ອຸປະກອນຂອງທ່ານກ່ອນ. ປະຕິບັດຕາມຄຳແນະນຳລະອຽດຂອງ ສູນຊ່ວຍເຫຼືອ ເພື່ອໂອນຍ້າຍໄຟລ໌ໄໃສ່ eReader ທີ່ຮອງຮັບ.
